We are live on ! Find out more
EVFM

Evofem Biosciences, Inc. Common Stock
EVFM

Delisted

EVFM was delisted on the 10th of August, 2022.

Back to rankings

103 hedge funds and large institutions have $74.5M invested in Evofem Biosciences, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 18

63% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 19

11% more funds holding

Funds holding: 93 → 103 (+10)

7% less capital invested

Capital invested by funds: $80M → $74.5M (-$5.48M)

14% less call options, than puts

Call options by funds: $1.05M | Put options by funds: $1.22M

Holders
103
Holders Change
+10
Holders Change %
+10.75%
% of All Funds
1.81%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
31
Increased
31
Reduced
19
Closed
18
Calls
$1.05M
Puts
$1.22M
Net Calls
-$167K
Net Calls Change
-$676K

Top Buyers

Rank Fund Capital Flow
1
MS
Maven Securities
Jersey
+$8.33M
2
CCM
CAAS Capital Management
New York
+$7.08M
3
BBA
Baker Bros. Advisors
New York
+$6.93M
4
GLA
Great Lakes Advisors
Illinois
+$5.14M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.72M

Top Sellers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
-$10.3M
2
Verition Fund Management
Verition Fund Management
Connecticut
-$362K
3
Squarepoint
Squarepoint
New York
-$239K
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$232K
5
AC
Aristides Capital
Kentucky
-$222K
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
1
Invesco
Georgia
$16.3M -$10.3M -227,023 -27%
BlackRock
2
BlackRock
New York
$9.81M +$1.19M +26,275 +8%
Vanguard Group
3
Vanguard Group
Pennsylvania
$7.29M +$1.72M +37,886 +16%
MS
4
Maven Securities
Jersey
$4.83M +$8.33M +183,333 New
BBA
5
Baker Bros. Advisors
New York
$4.72M +$6.93M +152,381 +556%
HA
6
Heartland Advisors
Wisconsin
$4.65M +$253K +5,567 +3%
CCM
7
CAAS Capital Management
New York
$4.09M +$7.08M +155,687 New
GLA
8
Great Lakes Advisors
Illinois
$2.97M +$5.14M +113,137 New
Geode Capital Management
9
Geode Capital Management
Massachusetts
$2.31M +$245K +5,398 +7%
State Street
10
State Street
Massachusetts
$2.05M +$42.5K +935 +1%
Northern Trust
11
Northern Trust
Illinois
$1.45M -$86.8K -1,909 -3%
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$1.26M +$1.59M +35,084 +271%
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$977K +$444K +9,775 +36%
TWMP
14
Taylor Wealth Management Partners
Massachusetts
$954K +$569K +12,522 +53%
LCM
15
Laurion Capital Management
New York
$700K +$1.21M +26,667 New
DC
16
Davenport & Co
Virginia
$699K +$315K +6,933 +35%
Millennium Management
17
Millennium Management
New York
$612K +$155K +3,401 +17%
SFM
18
Soros Fund Management
New York
$610K +$1.06M +23,237 New
Bank of America
19
Bank of America
North Carolina
$583K +$986K +21,685 +4,053%
Point72 Asset Management
20
Point72 Asset Management
Connecticut
$545K +$943K +20,745 New
SG Americas Securities
21
SG Americas Securities
New York
$474K +$821K +18,066 New
GCP
22
GSA Capital Partners
United Kingdom
$464K +$30.3K +666 +4%
N
23
Nuveen
North Carolina
$459K -$33K -727 -4%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$446K +$131K +2,872 +20%
Goldman Sachs
25
Goldman Sachs
New York
$441K +$218K +4,796 +40%
1
2 3 4 5

EVFM Hedge Fund Activity: Q1 2021 in Review

103 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q1 2021, worth a combined $74.5M — down 6.8% from $80M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new EVFM positions and 18 closed out — a net gain of 13 holders — while 31 added to existing stakes and 19 trimmed.

The largest buyer was Maven Securities, opening a new position worth an estimated $8.33M. The largest seller was Invesco, cutting an estimated $10.3M.

  • 103 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q1 2021, up from 93 in Q4 2020.
  • Funds reported $74.5M of Evofem Biosciences, Inc. Common Stock stock for Q1 2021, down 6.8% quarter-over-quarter.
  • 31 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q1 2021 and 18 closed out, a net change of +13 holders.
  • The largest Evofem Biosciences, Inc. Common Stock buyer in Q1 2021 was Maven Securities, an estimated $8.33M added.
  • The largest Evofem Biosciences, Inc. Common Stock seller in Q1 2021 was Invesco, an estimated $10.3M sold.

Based on aggregated 13F filings for Q1 2021.